Symbiox Investme (539278)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a 74% discount to stated book value of ₹10.94 per share, with P/B just 0.26.
• Positive ROCE of 0.82% suggests the small capital base is not completely non-productive.
• Tiny ₹9 Cr market cap leaves room for a meaningful re-rating if assets are realized or operations restart.
• No earnings impairment via P/E multiple because the price is primarily supported by the balance sheet, not optimistic profit assumptions.

Concerns

• Latest quarter shows zero sales and zero net profit; sales growth is -80% and profit growth is -93.75%.
• Negative ROE of -0.50% and Piotroski F-Score of 3/9 point to weak financial health.
• No promoter holding data makes governance and management alignment unverifiable.
• Zero dividend yield and zero earnings mean value depends entirely on whether the ₹10.94 book value is real and realizable.

AI Analysis

At ₹2.87, Symbiox Investme is down to a market cap of just ₹9 Cr against a stated book value of ₹10.94 per share. That is a P/B of 0.26 — a 74% discount. A classic Graham asset play at first glance. But my first question is always: does the business earn a return on those assets? The answer is no. Sales have collapsed by 80%, net profit is down 93.75%, and the latest quarter shows both sales and net profit at zero. ROE is -0.50%, and ROCE is just 0.82%. This is not a living, compounding business; it is a shell of one. The Piotroski F-Score of 3/9 also tells me the financial health is poor. I never buy a stock merely because it looks cheap. I buy either great businesses at fair prices or assets at a deep enough discount that I can get my money out. Here, the discount is deep, but there is no clue how value will be realized. There is no dividend yield, no promoter holding data, and no earnings to anchor the P/E. The ₹10.94 book value could be worth much less if those assets are illiquid or overvalued. In a 9 crore market cap, any buyer must be careful about governance and exit. I would not rush in. I would watch for a catalyst — a sale, a buyback, or a genuine restart of operations. Until then, this is a statistical cheap stock, not a certain asset play. In the current form, I'd rather leave it for the speculator.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer